News & Events about Cymabay Therapeutics Inc.
NEWARK, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need announced the closing, on January 26, 2023, of its previously ...
CymaBay Therapeutics, Inc. (NASDAQ:CBAY Get Rating) has been given an average recommendation of Buy by the six analysts that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy ...
Shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY Get Rating) have been given an average recommendation of Buy by the six brokerages that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation, two have assigned ...
Advances strategy to partner seladelpar for PBC outside U.S. Brings in approximately $34.0 million upfront payment Japan represents an important market with no currently approved second line treatment NEWARK, Calif. and TOKYO, Jan. 08, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: ...
Globe Newswire
3 months ago
NEWARK, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced encouraging seladelpar data in patients with...